Drug Profile
HIV vaccine - AVANT
Alternative Names: HIV-Therapore™ VaccineLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics; Walter Reed Army Institute of Research
- Developer Celldex Therapeutics Inc; Walter Reed Army Institute of Research
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; HIV infections
Most Recent Events
- 06 Feb 2017 Discontinued - Phase-I for HIV infections treatment in USA (IM)
- 06 Feb 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 13 May 2004 Phase-I clinical trials in HIV infections treatment in USA (unspecified route)